Participant flow

Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer · Source last updated 2021-03-11

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Metastatic breast cancer PD-0332991: Given orally, 125 mg QD on a 21-day

   id

   FG000

   title

   Arm 1

2. description

   Metastatic colorectal cancer that harbors the Kras or BRAF mutation PD-0332991: Given orally, 125 mg QD on a 21-day

   id

   FG001

   title

   Arm 2

3. description

   Advanced or metastatic esophageal and/or gastric cancer PD-0332991: Given orally, 125 mg QD on a 21-day

   id

   FG002

   title

   Arm 3

4. description

   Cisplatin-refractory, unresectable germ cell tumors PD-0332991: Given orally, 125 mg QD on a 21-day

   id

   FG003

   title

   Arm 4

5. description

   Any tumor type if tissue tests positive for CCND1 amplification, CDK4/6 mutation , CCND2 amplification OR any other functional alteration at the G1/S checkpoint. PD-0332991: Given orally, 125 mg QD on a 21-day

   id

   FG004

   title

   Arm 5

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         63

      2. group Id

         FG001

         num Subjects

         18

      3. group Id

         FG002

         num Subjects

         19

      4. group Id

         FG003

         num Subjects

         30

      5. group Id

         FG004

         num Subjects

         11

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         63

      2. group Id

         FG001

         num Subjects

         18

      3. group Id

         FG002

         num Subjects

         19

      4. group Id

         FG003

         num Subjects

         30

      5. group Id

         FG004

         num Subjects

         11

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         0

      3. group Id

         FG002

         num Subjects

         0

      4. group Id

         FG003

         num Subjects

         0

      5. group Id

         FG004

         num Subjects

         0

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice